pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1h ago·1 min read
save

Massachusetts moves to revoke all RegalCare nursing home licenses after Boston Globe investigation

Oct 20, 2026·read at STAT ↗RegulatoryNegative

Massachusetts regulators announced on Oct 13 that they will revoke every nursing home license held by RegalCare, a New Jersey‑based operator that acquired a dozen facilities in the state after the pandemic.

The revocation follows a Boston Globe Spotlight investigation that documented steep cuts to nursing and other services after CEO Eli Mirlis bought the homes, directing funds to his related businesses and lowering care quality.

While the licenses are being withdrawn, the Department of Public Health said RegalCare will not lose immediate control of the properties; instead the homes will be placed under enhanced state monitoring.

The action highlights increased regulatory scrutiny of nursing home operators and underscores concerns about cost‑cutting measures that compromise resident care.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: State regulators move to seize licenses from nursing home chain that was focus of Boston Globe investigation”

read at STAT ↗
437 words · retrieved 32m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ROCHE
topics
ApprovalOncology

related stories

  • 8h agoEyepoint, Enlivex enact heavy layoffsBioSpace
  • Aug 25STAT+: Pharmalittle: We’re reading about RFK Jr. vaccine disclosures, a Merck loss over Medicare prices, and moreSTAT
  • Aug 24Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanismFierce Biotech
  • Aug 20Chutes & Ladders—Neumora shuffles leadership ahead of INDFierce Biotech
  • Aug 10Labcorp nabs FDA green light for BRAF melanoma diagnosticFierce Biotech